Business Wire

ZEDRA Announces Milestone Acquisition of Global Expansion Specialist Fitzgerald & Law.

14.9.2020 10:00:00 EEST | Business Wire | Press release

Share

ZEDRA, the fast growing global specialist in Corporate, Fund and Active Wealth Solutions has announced the acquisition of Fitzgerald & Law (F&L), London’s leading firm of global expansion advisers. In addition to offering a wide range of specialised expansion advice to companies setting up in the UK, F&L provides a full suite of award-winning tax, HR and financial compliance services that supports those companies as they grow. At the same time as this transaction, ZEDRA will acquire the Global Expansion Advisory Network operating in over 70 countries, of which F&L is a founding firm. F&L’s continued membership of the GEA Network means that companies expanding into countries other than the UK can receive the same unparalleled support.

This acquisition marks a step change for ZEDRA’s corporate services offering and will substantially enlarge the Group’s reach to fast-growing US technology companies. F&L has a particular focus on helping US companies wishing to establish and grow a UK presence, and more broadly advises companies from all over the world on expanding their footprint in other territories globally. F&L has a strong track record in multi-territory HR consulting, international tax compliance, corporate compliance and accounting services.

The acquisition will bolster ZEDRA’s presence in the all-important London market with F&L’s London team of over 70 helping to double ZEDRA’s workforce in the UK. ZEDRA also welcomes a team of 14 in Romania who provide vital support to the outsourcing services function. The F&L San Francisco office will continue to play a key role in business development and supporting clients on the US West Coast.

Ivo Hemelraad, ZEDRA Chief Executive Officer, commented, “We are delighted to welcome the employees and clients of Fitzgerald & Law to ZEDRA and to extend our corporate services reach to the US West Coast where F&L has an enviable and growing reputation. Adding their knowledge and expertise to our Group will significantly extend the support we can offer to our international corporate clients and help them optimise their global expansion strategies.”

Gabriel Parrish, Senior Partner at F&L added, “Joining ZEDRA at this time with its global footprint of offices and international client base is a natural fit for F&L, and a logical step forward in our growth plans. Our clients will now have access to an additional range of services to support their business ambitions.”

Fitzgerald & Law will ultimately rebrand to ZEDRA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries :

https://www.zedra.com/boilerplate/

Guy Stephenson
Nacelle
Tel: +44 20 8333 9125

Fitzgerald & Law

Kirstie Leadley
+44 (0)7988 719736
kleadley@fitzandlaw.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye